MX368854B - Composiciones que comprenden benzodiazepinas de acción corta. - Google Patents

Composiciones que comprenden benzodiazepinas de acción corta.

Info

Publication number
MX368854B
MX368854B MX2014014225A MX2014014225A MX368854B MX 368854 B MX368854 B MX 368854B MX 2014014225 A MX2014014225 A MX 2014014225A MX 2014014225 A MX2014014225 A MX 2014014225A MX 368854 B MX368854 B MX 368854B
Authority
MX
Mexico
Prior art keywords
compositions
short
acting benzodiazepines
benzodiazepines
acting
Prior art date
Application number
MX2014014225A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014225A (es
Inventor
Aitken Graham John
James Baillie Alan
Richard Ward Kevin
Peacock Thomas
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368854(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of MX2014014225A publication Critical patent/MX2014014225A/es
Publication of MX368854B publication Critical patent/MX368854B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014014225A 2012-05-22 2013-05-22 Composiciones que comprenden benzodiazepinas de acción corta. MX368854B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (2)

Publication Number Publication Date
MX2014014225A MX2014014225A (es) 2015-06-17
MX368854B true MX368854B (es) 2019-10-18

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014225A MX368854B (es) 2012-05-22 2013-05-22 Composiciones que comprenden benzodiazepinas de acción corta.

Country Status (41)

Country Link
US (2) US20150148338A1 (enExample)
EP (1) EP2852389B1 (enExample)
JP (1) JP6313286B2 (enExample)
KR (1) KR102116737B1 (enExample)
CN (2) CN104968348B (enExample)
AP (1) AP2014008084A0 (enExample)
AR (1) AR092008A1 (enExample)
AU (1) AU2013265295B2 (enExample)
BR (1) BR112014029108B1 (enExample)
CA (1) CA2874247C (enExample)
CL (1) CL2014003171A1 (enExample)
CO (1) CO7151503A2 (enExample)
DK (1) DK2852389T3 (enExample)
EA (1) EA032119B1 (enExample)
EC (1) ECSP14032553A (enExample)
ES (1) ES2651389T3 (enExample)
FR (1) FR21C1043I2 (enExample)
GE (1) GEP20186852B (enExample)
HR (1) HRP20171872T1 (enExample)
HU (2) HUE037734T2 (enExample)
IL (1) IL235789B (enExample)
LT (2) LT2852389T (enExample)
LU (1) LUC00230I2 (enExample)
MA (1) MA37581B1 (enExample)
MX (1) MX368854B (enExample)
MY (1) MY185117A (enExample)
NL (1) NL301130I2 (enExample)
NO (2) NO2852389T3 (enExample)
NZ (1) NZ702063A (enExample)
PE (1) PE20150683A1 (enExample)
PH (1) PH12014502608B1 (enExample)
PL (1) PL2852389T4 (enExample)
PT (1) PT2852389T (enExample)
RS (1) RS56660B1 (enExample)
SG (1) SG11201407710VA (enExample)
SI (1) SI2852389T1 (enExample)
TN (1) TN2014000479A1 (enExample)
TW (1) TWI590826B (enExample)
UA (1) UA115063C2 (enExample)
WO (1) WO2013174883A1 (enExample)
ZA (1) ZA201408412B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および/または鎮静のための注射用組成物
CN106165546A (zh) 2014-02-10 2016-11-23 拜欧卢米克有限公司 在控制光合生物的特征方面及与之相关的改进
CN106413378A (zh) 2014-03-14 2017-02-15 拜欧卢米克有限公司 提高作物产量和/或质量的方法
US9994578B2 (en) 2014-07-23 2018-06-12 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Benzodiazepine derivative and use thereof
JP2017529076A (ja) 2014-09-17 2017-10-05 バイオルミック リミテッド 種子処理の方法およびその結果として得られる生産物
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
WO2017178663A1 (en) 2016-04-14 2017-10-19 Paion Uk Limited Orally inhaled and nasal benzodiazepines
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
WO2018037281A1 (en) 2016-08-22 2018-03-01 Biolumic Limited System, device and methods of seed treatment
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
AU2018293468A1 (en) 2017-06-29 2020-01-30 Biolumic Limited Method to improve crop yield and/or quality
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
WO2024126745A1 (en) * 2022-12-16 2024-06-20 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
WO2024251275A1 (zh) * 2023-06-09 2024-12-12 成都麻沸散医药科技有限公司 一种氮杂*类化合物及其组合物和应用
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
WO1996020941A1 (de) 1995-01-06 1996-07-11 F. Hoffmann-La Roche Ag Hydroxymethyl-imidazodiazepine und deren ester
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
JP2008530134A (ja) * 2005-02-15 2008-08-07 エラン ファーマ インターナショナル リミテッド ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
KR20170091770A (ko) * 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US9102677B2 (en) * 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
TWI590826B (zh) 2017-07-11
US20220040198A1 (en) 2022-02-10
SG11201407710VA (en) 2015-01-29
PL2852389T4 (pl) 2022-02-21
IL235789A0 (en) 2015-01-29
UA115063C2 (uk) 2017-09-11
NZ702063A (en) 2016-11-25
EA032119B1 (ru) 2019-04-30
ZA201408412B (en) 2016-09-28
SI2852389T1 (en) 2018-02-28
IL235789B (en) 2019-07-31
TW201400119A (zh) 2014-01-01
LT2852389T (lt) 2017-12-27
US20150148338A1 (en) 2015-05-28
CA2874247C (en) 2020-07-28
CA2874247A1 (en) 2013-11-28
CL2014003171A1 (es) 2015-06-19
TN2014000479A1 (en) 2016-03-30
CO7151503A2 (es) 2014-12-29
ECSP14032553A (es) 2018-11-30
KR102116737B1 (ko) 2020-05-29
LTPA2021521I1 (enExample) 2021-10-11
CN104968348B (zh) 2018-04-17
KR20150009601A (ko) 2015-01-26
CN108578413A (zh) 2018-09-28
RS56660B1 (sr) 2018-03-30
MA20150233A1 (fr) 2015-07-31
EA201492160A1 (ru) 2015-10-30
NL301130I2 (nl) 2021-10-25
MA37581B1 (fr) 2016-07-29
FR21C1043I1 (enExample) 2021-11-19
FR21C1043I2 (fr) 2022-10-07
HUE037734T2 (hu) 2018-09-28
HRP20171872T1 (hr) 2018-02-23
MX2014014225A (es) 2015-06-17
JP6313286B2 (ja) 2018-04-18
NL301130I1 (enExample) 2021-09-22
AR092008A1 (es) 2015-03-18
PH12014502608A1 (en) 2015-01-21
BR112014029108A2 (pt) 2017-06-27
GEP20186852B (en) 2018-05-25
PH12014502608B1 (en) 2019-11-27
JP2015517552A (ja) 2015-06-22
NO2021041I1 (no) 2021-09-20
LUC00230I2 (enExample) 2022-10-07
NO2852389T3 (enExample) 2018-03-17
HUS2100040I1 (hu) 2021-10-28
WO2013174883A1 (en) 2013-11-28
AU2013265295B2 (en) 2017-08-31
BR112014029108B1 (pt) 2022-02-08
PT2852389T (pt) 2017-12-13
EP2852389B1 (en) 2017-10-18
AP2014008084A0 (en) 2014-11-30
AU2013265295A1 (en) 2015-01-22
DK2852389T3 (en) 2017-12-18
PE20150683A1 (es) 2015-06-03
LTC2852389I2 (enExample) 2024-11-25
MY185117A (en) 2021-04-30
CN104968348A (zh) 2015-10-07
HK1208164A1 (en) 2016-02-26
ES2651389T3 (es) 2018-01-26
PL2852389T3 (pl) 2018-02-28
EP2852389A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
MX368854B (es) Composiciones que comprenden benzodiazepinas de acción corta.
UY4236Q (es) Configuración aplicada en zapato
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
MX373334B (es) Composiciones y métodos.
BR302013001738S1 (pt) Configuração aplicada em mobiliário.
SI2976106T1 (sl) Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec
PL2882440T3 (pl) Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
EP2902430A4 (en) POLYETHERCOPOLYMER, NETWORKY POLYETHERCOPOLYMER COMPOSITION AND ELECTROLYTE
SI2802320T1 (sl) Triciklične spojine, sestavki, ki jih obsegajo in njihove uporabe
CL2015001730A1 (es) Compuestos triciclos inhibidores del canal cftr; composicion y combinacion farmaceutica; y uso en el tratamiento de la enfermedad renal poliquistica y diarrea.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
EP2881444A4 (en) Water-repellent and oil-repellent composition and articles therewith
EP3057441A4 (en) Composition preventing necrotic enteritis in galloanserans
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
WO2014146111A3 (en) Analgesic compounds and methods of use
BR112014000232A8 (pt) primeira composição, segunda composição e artigo
CL2014003484A1 (es) Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
UY4198Q (es) Nuevo Diseño de una Plancha de Blisters en Forma de ?A?.
UY4233Q (es) Configuración aplicada en zapato
EP3036849A4 (en) Bs and ue, and methods used in the same
UY34594A (es) Derivados heterocíclicos bicíclicos, su preparación y su aplicación en terapéutica
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit
PL2874601T3 (pl) Kompozycja, w szczególności kompozycja farmaceutyczna, w szczególności do podawania przy chrypce
HIRONO The management of private railway company in Colonial Taiwan, Taipei–Case study of Taipei Railway

Legal Events

Date Code Title Description
FG Grant or registration